BLOOD, WHOLE
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Paradigm Healthother_biologicalActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
40 Active assets in the Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Memorial Sloan Kettering Cancer Center | Phase 3 | BB |
Pembrolizumab Diwakar Davar | Phase 3 | BB |
Nivolumab Memorial Sloan Kettering Cancer Center | Phase 2 | BB |
TRASTUZUMAB UNICANCER | Phase 3 | BB |
Capecitabine Shanghai Zhongshan Hospital | Phase 3 | B |
View all 50 →
Same molecule, other indications
BLOOD, WHOLE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →